---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-008051"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:02:44.715714+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GNI Group FY2023 revenue up 49% to ¥26.0B; Gyre expects Hydronidone IND in 2024; settles litigation for $385K

## Summary
- GNI Group FY2023 revenue ¥26,010M (+49% YoY), operating profit ¥13,108M (+851%), net profit ¥9,504M vs loss prior year.
- Basic EPS ¥169.50; FY2024 guidance: revenue ¥39,566M (+52%), operating profit ¥16,286M.
- Gyre expects to submit Hydronidone IND in US by end of 2024; Phase 3 trial in China last patient observation in 2024.
- Gyre (as successor to Catalyst) settles shareholder litigation over business combination; pays $385K in attorneys' fees.

## SEC filing metadata
- accession: 0001140361-24-008051
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036124008051/0001140361-24-008051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036124008051/ef20021723_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-008051
- JSON: https://secwatch.observer/filing/0001140361-24-008051.json
- Plain text: https://secwatch.observer/filing/0001140361-24-008051.txt

## Key facts
- Earnings Releases
  GYRE THERAPEUTICS, INC. reported FY2023 (January to December) results: revenue 26,010, net income 9,504, EPS 169.50. Guidance reaffirmed.
  - Period: FY2023 (January to December)
  - Revenue: 26,010
  - Net income: 9,504
  - EPS: 169.50
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Profit attributable to owners of the parent Total comprehensive income for the year Million yen % Million yen % Million yen % Million yen % Million yen % Million yen % FY2023 26,010 49.3 13,108 851.3 12,612 - 9,504 - 8,094 - 10,662 - FY2022 17,418 37.3 1,377 (15.2) 767 (30.6) (868) - 388 (63.5) 187 (88.1) Basic earnings per share Diluted earnings per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036124008051/0001140361-24-008051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.